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Abstract 23 
Polymer microparticles are widely used as acellular drug delivery platforms in regenerative 24 
medicine, and have emerging potential as cellular scaffolds for therapeutic cell delivery. In 25 
the clinic, PLGA microparticles are typically administered intramuscularly or subcutaneously, 26 
with the clinician and clinical application site determining the precice needle gauge used for 27 
delivery. Here, we explored the role of needle diameter in microparticle delivery yield, and 28 
develop a modified viscosity formulation to improve microparticle delivery across a range of 29 
clinically relevent needle diameters.  We have identified an optimal biocompatible 30 
formulation containing 0.25% pluronic F127 and 0.25% carboxymethyl cellulose, which can 31 
increase delivery payload to 520% across needle gauges 21-30G, and note that needle 32 
diameter impacts delivery efficacy. We use this formulation to increase the delivery yield of 33 
PLGA microparticles, and seperately, PLGA-cell scaffolds supporting viable mesenchymal 34 
stem cells (MSCs), demonstrating the first in vitro delivery of this cell scaffold system. 35 
Together, these results highlight an optimal formulation for the delivery of microparticle and 36 
microparticle-cell scaffolds, and illustrate how careful choice of delivery formulation and  37 
needle size can dramatically impact delivery payload.  38 
  39 
1. Introduction  40 
Poly (DL-lactic acid-co-glycolic acid) (PLGA) materials are widely used therapeutics with 41 
applications in drug delivery,[1-3] tissue engineering,[4] and cellular scaffolding.[5, 6] In drug 42 
delivery applications, PLGA microparticles offer tunable, biodegradeable kinetic release 43 
profiles. They are FDA approved for a variety of applications, and can often be administered 44 
via localised or systemic injection.[2, 7, 8] Larger 3-dimensional PLGA structures have also 45 
been surgically implanted as cellular scaffolds for regenerative medicine,[9, 10]  however there 46 
are limited examples of systems combining the extracellular support matrix provided by 47 
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PLGA [5, 11] with the tunable kinetic release of soluble factors.[7] Through this combination of 48 
a physical support matrix and soluble cellular cues,  microparticle cell scaffold systems with 49 
controlled release properties are able to support and direct transplanted cell behaviour.  50 
A current challenge in the delivery of microparticles, cells, or microparticle-cell combination 51 
therapies lies in maintaining an effective therapeutic dose across varied application routes. In 52 
many systems, a common clinical administration route is the localised injection of materials 53 
using either pre-filled or self-filled syringes together with a needle.[12-15] Selection of an 54 
appropriate needle gauge depends on the therapeutic application; finer needles of 29G are 55 
often used for spatially accurate delivery of materials to the spinal cord, compared to 14G 56 
needles frequently used for intramuscular injection.[16-20] In cell-only systems, recent studies 57 
have suggested that injection parameters (including needle gauge, flow rate and applied force) 58 
can affect both the number of cells delivered and the ability of these cells to undergo 59 
phenotypic differentiation,[21-24] however these studies have yet to be applied to delivery of 60 
acellular microparticle systems. 61 
Maintaining an effective therapeutic dose across a broad range of administration routes 62 
remains an ongoing consideration for the clinical application of drug delivery systems.[25] [26] 63 
To our knowledge, there has yet to be a study on the effect of injection parameters on delivery 64 
of either PLGA microparticles alone, or PLGA microparticles in conjunction with cells.  65 
Here, we explore modified viscosity systems to enhance both microparticle delivery and 66 
microparticle-cell scaffold delivery across a range of clinically relevant needle gauges. First, 67 
we explore PLGA particle delivery across a range of needle gauges with controlled plunger 68 
force. Next, we investigate modified delivery formulations using the thickening agent 69 
carboxymethylcellulose (CMC)[27] and the amphiphilic polymer pluronic F127,[28] probing 70 
their ability to modify viscosity and their effect on particle delivery across needle sizes. 71 
Finally, we investigate the effect of our lead formulation on the viability of human MSCs, and 72 
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demonstrate the use of our formulation in delivering multifunctional PLGA microparticle 73 
scaffolds with human MSCs in vitro.   74 
2. Materials and Methods  75 
2.1 Fabrication of PLGA microparticles  76 
Non-porous PLGA particles were fabricated using 20% PLGA (50:50, 52 kDa Lakeshore 77 
Biomaterials) in dichloromethane (DCM) (Fischer) by either a single or double emulsion 78 
method. In the single emulsion method, the polymer solution was homogenised in 250 mL 79 
of 0.3% polyvinyl alcohol (13-24 kDa, Sigma-Aldrich) using a high speed Silverson L5M 80 
homogeniser. The resulting emulsion was left stirring at 300 RPM until particles hardened. 81 
In the double emulsion method, 100 µL of an aqueous solution containing 10 mg 82 
Amoxicillin (Abcam) was homogenised in the polymer solution. The resultant primary 83 
water in oil (w/o) emulsion was then homogenised again in the 0.3% PVA and the resultant 84 
water in oil in water (w/o/w) double emulsion was left stirring until particles hardened. 85 
Particles were extracted by centrifugation, washed, and lyophilised before being stored at -86 
20⁰C until use.   Porous PLGA particles were produced using a double emulsion method as 87 
previously described.[6] Briefly, 20% (w/v) PLGA in dichloromethane was treated with 88 
phosphate buffered saline (PBS, Gibco) as a porogen. Post fabrication, the particles were 89 
treated with ethanolic sodium hydroxide (sodium hydroxide (Sigma-Aldrich) and absolute 90 
ethanol (Fischer)) to enhance surface porosity. The particles were then extracted by 91 
centrifugation, washed, and lyophilised before being stored at -20⁰C until use. 92 
Particles were characterised using scanning electron microscopy and laser diffraction. 93 
Briefly, particles were loaded onto carbon disks on aluminium stubs (Agar Scientific), 94 
sputter coated with gold (Balzers Union Ltd.) and imaged on an JEOL 6060L system. The 95 
mean diameter and particle size distribution were analysed using a Coulter LS230 particle 96 
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size analyser (Beckman, UK). Particle size distribution was then determined as a function 97 
of the particle diffraction and plotted as a function of volume percentage. 98 
2.2 Delivery formulations 99 
Particles were resuspended at 5 mg/mL in DMEM (Gibco), containing between 0-10% 100 
pluronic F127 (Sigma-Aldrich) or 0-10% medium viscosity sodium carboxymethylcellulose 101 
(CMC)  (Sigma-Aldrich). Combined formulations containing between 0-0.5% pluronic and 0-102 
0.5% CMC were also prepared. Formulation solutions were kept at 4⁰C until use. Solution 103 
viscosity was measured using a rheometer with cone and plate geometry at 0.1° angle (Anton 104 
Parr- Physica MCR 301)), using a shear ramp from 0-100 1/s at 25°C.   105 
2.3 Particle injection 106 
PLGA microparticles (5.0 mg) were suspended in polymer/media formulation (1.0 mL) in 1.5 107 
mL Eppendorf tubes under repeated pipetting and vortexing. The total volume was drawn up 108 
into a 1 mL disposable syringe (BD) and a needle (gauges 21G, 23G, 25G, 27G, 30G (BD 109 
Microlance)) fitted to the syringe prior to ejection of the total volume into a new Eppendorf 110 
tube.  A sample (10 µL) was taken from the ejected volume and particles were counted using 111 
a haemocytometer. For comparison, particles were also ejected through needles without a 112 
syringe to provide a control. Injections were considered to have failed when the contents of 113 
the syringe could not be ejected using a mechanically controlled syringe pump. This is usually 114 
due to a blockage in the needle or aggregation of the suspension at the syringe tip, resulting in 115 
the syringe contents not being completely emptied. Injection failures are recorded and 116 
measured in counts, and the calculated values illustrates the percentage of “failed” injections 117 
per condition. 118 
2.4 Injection forces and calculated shear rates 119 
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For each needle-syringe combination, the initial and glide force were determined using a 120 
texture analyser (TA.HD plus, Stable micro systems).  1 mL of formulation was loaded into a 121 
1 mL syringe (BD), and fitted with an appropriate needle into the injection rig. A 10 mm 122 
cylinder probe was lowered into contact with the plunger, with no pre-test force, before a 1 123 
mm/s ejection rate was applied in compression mode. The initial force was calculated as the 124 
force required to overcome the resistance to movement of the plunger, whereas the glide force 125 
was calculated as the average force required to evacuate the syringe at 1 mm/s.  For 126 
formulations tested with microparticles, a concentration of 5 mg/mL particles suspended in 1 127 
mL solution was used. Shear rates were calculated using Poiseuilles equation;  128 
𝛾 =
4𝑄
𝜋𝑟3
 129 
Where γ is shear rate in s-1, Q is flow rate in cm3/s, and r is needle radius in cm. Shear rates 130 
were calculated using both experimental flow rate (for 1 mm/s plunger ejection) and 131 
theoretical flow rates 1 ml/hour and 20 ml/hour expected to be used in clinic, described in 132 
Table 2.  133 
2.5 PLGA microparticle release studies 134 
In vitro testing of the controlled release of Amoxicillin encapsulated within PLGA 135 
microparticles was performed using Transwell inserts (Corning, UK). 25 mg of PLGA 136 
microparticles were suspended in 1.5 mL of the described formulations, and incubated at 137 
37 °C. The concentration of Amoxicillin in release medium was quantified by UV 138 
detection at 300 nm using a plate reader (Tecan) with concentration determined from a 139 
calibration curve. 140 
2.6 Cell viability  141 
  
7 
 
Human bone marrow derived mesenchymal stem cells (MSCs) (UE6E7T-11 cells sourced 142 
from the Japanese Stem Cell Bank) were used for all cellular assays. The Prestoblue cell 143 
viability assay (Invitrogen Life Sciences, UK) was performed 1 and 24 hours post-seeding 144 
(n=6). Each sample was submerged in 1 mL of 10% Prestoblue (Invitrogen Life Sciences, 145 
UK) in media; all samples were incubated at 37°C for 30 minutes. Triplicate 100 µL media 146 
samples from each well were read on a Tecan plate reader with the excitation wavelength set 147 
to 535 nm and the emission wavelength set at 615 nm. 148 
2.7 Injection of cells cultured on particles 149 
Porous particles were treated with Tween and then antibiotic/antimycotic solution (Sigma-150 
Aldrich). Commercially available human mesenchymal stem cells (MSCs) (Japanese Stem 151 
Cell Bank) were seeded at 200,000 per well in 12-well plates, with 8mg PLGA particles 152 
added per well, and incubated overnight at 37 °C in DMEM medium supplemented with 10% 153 
foetal calf serum, 1% antibiotic/ antimycotic solution, 1% L-glutamine (2 mM) and 1% non-154 
essential amino acids (Sigma-Aldrich).  Wells were centrifuged, and the cell pellet re-155 
suspended in DMEM or formulation conditions. As described previously, this suspension was 156 
injected into a fresh 12-well plate, and incubated for 10 minutes with 10% Presto blue at 157 
37 °C.  Cell number per well was quantified using a Tecan plate reader. Samples were 158 
formalin fixed for 20 minutes at room temperature, washed with PBS multiple times and then 159 
imaged by SEM. 160 
2.8 Delivery efficacy   161 
Delivery efficacy was calculated by comparing the number of particles delivered using a 162 
specific formulation and needle combination to the number of particles delivered in a basal 163 
media solution. Particles were counted using a hemocytometer. For example, to compare the 164 
delivery efficacy of particles suspended in basal media through needle-free syringes and 27G 165 
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needles, a suspension of PLGA particles was loaded into at least six identical syringes, three 166 
of which were uncapped and three capped with 27G needles. Syringes were loaded onto the 167 
controlled rate syringe pump, and ejected at constant plunger speed of 1 mm/s. An aliquot of 168 
the ejected solution was transferred to a hemocytometer and the number of ejected particles 169 
counted. To calculate delivery efficiacy, we averaged the number of particles for each 170 
condition and calculated efficacy as follows;  171 
𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑦 𝑒𝑓𝑓𝑖𝑐𝑎𝑐𝑦 =
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑒𝑑 𝑖𝑛 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 𝑋
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑑𝑒𝑙𝑖𝑣𝑒𝑟𝑒𝑑 𝑖𝑛 𝑏𝑎𝑠𝑎𝑙 𝑚𝑒𝑑𝑖𝑎
× 100 172 
2.9 Statistical analysis  173 
Statistical analysis was performed using GraphPad Prism (Version 7) software. ANOVA 174 
analysis was used for all statistical testing, performed on data from between 3-6 repeat 175 
experiments. Analysis is considered significant, and the * designation is assigned, if  p>0.05 176 
*, p>0.01 **, p>0.001 ***, p>0.0001 ****. Bar graphs represent the mean of 3-6 individual 177 
repeats, with associated error bars to show the standard error in the mean (SEM). Details of  178 
individual statistical tests (ie. one way or two way ANOVA, number of repeats) are provided 179 
in the figure caption for each graph.  180 
3. Results and Discussion 181 
3.1The effect of needle gauge on microparticle delivery 182 
We fabricated PLGA microparticles of 27 µm diameter as described in section 2.1 (Figure 183 
1A), and investigated delivery efficacy through needles between 21-30G, corresponding to 184 
internal needle diameters currently used in clinic ranging from over 500 µm to around 160 µm 185 
(Table 1). Using a syringe pump set up with constant flow rate of 1 mm/s, we evaluated the 186 
ejection of PLGA microparticles suspended in basal media solution through a range of needle 187 
gauges (Figure 1B). All needle gauges tested were able to deliver the microparticles, however 188 
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we find that narrower needle gauges of 27G and 30G failed to deliver microparticle solutions 189 
as effectively as either needle free or large-bore needle systems, with delivery efficacy 190 
reduced to 61% in 27G needles compared to needle free systems. Given the internal needle 191 
diameters of 27G and 30G needles (210 µm and 160 µm respectively) are wider than the 26.9 192 
µm (+/- SD 11.2 µm) diameter of the microparticles (Figure 1A), this suggests that the 193 
particle delivery through narrow gauge needles is affected not only by particle size, but also 194 
the dynamics of the fluid ejection from the syringe. To explore this further, we investigated 195 
the effect of altering the solution viscosity, and so ejection fluid dynamics, of the delivery 196 
formulation in needle delivery systems.  197 
3.2 PLGA microparticle delivery using modified formulations 198 
Formulations containing the thickening agent carboxymethylcellulose (CMC) (Figure 1C), 199 
pluronic F127 (Figure 1D) to modulate wettability, and CMC/pluronic F127 (Figure 1E) 200 
combination formulations were tested for their ability to deliver PLGA microparticles. Figure 201 
1 demonstrates that increasing concentrations of either CMC or pluronic F127 in media 202 
significantly increased particle delivery, illustrated by the 400% increase of particle delivery 203 
in systems using either 5% pluronic F127  or 2% CMC, compared to un-supplemented media. 204 
We then investigated combination formulations with compositions of between 0.125-0.5% of 205 
CMC and pluronic F127 in media. Figure 1E illustrates that particle delivery was significantly 206 
improved in all combination formulations tested, and broadly increased as the concentration 207 
of CMC/pluronic F127 in solution increased.  208 
We calculated the shear rate used during our experimental injections at a constant plunger rate 209 
of 1 mm/s (Table 2). These values suggest our experimental injection system experiences low 210 
shear between 150-500/s. We examined the effect of formulation composition on viscosity at 211 
comparable shear rates between 1-100/s. Comparing the formulations, Figure 1F illustrates 212 
that the viscosity of each composition remains broadly constant against increasing shear 213 
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between 1-100/s. In systems with constant CMC concentration and varying pluronic F127 214 
concentration, viscosity measurements are similar, whilst viscosity measurements roughly 215 
double as the concentration of CMC doubles in the formulation, suggesting that viscosity 216 
properties are broadly driven by the CMC concentration in solution.[29, 30]  Given that many 217 
clincially administered injections are delivered at higher flow rates than those tested 218 
experimentally,[31, 32] we next calulcated the expected flow rate and shear rate during more 219 
rapid administration through various needle gauges (Table 2). Needles injecting flow rates of 220 
1 ml/hour and 20 ml/hour (flow rates more commonly used for clinical infusion regimes) 221 
experience much higher shear rates through similar needle gauges.  222 
At the shear rates tested here, supplementing basal media with pluronic acid and CMC can 223 
increase microparticle delivery. There are several potential explanations for this, including the 224 
changes in solution viscosity and the increased wetting of microparticles in these 225 
formulations. The increased solution viscosity may help to form a stable microparticle 226 
suspension during syringe evacuation, which prevents particles being forced to the side of the 227 
syringe. Particles at the side of syringe can be statically attracted to the syringe casing and are 228 
less likely to be ejected.[33] Additionally, Figure 1E indicates that increasing the total polymer 229 
concentration to above 0.5%, can increase delivery payload. It is likely that the negatively 230 
charged polymers help to combat static and attractive charges between the particles and the 231 
syringe, facilitating particle ejection.[8, 29] The combined effects of increased polymer 232 
concentration, particle wetting and increased viscosity, are likely responsible for the increase 233 
in delivery.   234 
3.3 Modified delivery formulations using clinical needle gauges  235 
All combination formulations tested demonstrated enhanced microparticle delivery compared 236 
to a basal media control in a 23G needle system. We then explored whether these combination 237 
formulations were able to enhance microparticle delivery across a range of clinically relevant 238 
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needle gauges.[16-18, 20, 34, 35] Figure 2A compares the number of microparticles delivered for 239 
each formulation in 21-27G needles, and Figure 2B summarises the average delivery across 240 
all needle gauges tested. There is a significant increase in particle delivery across all needle 241 
gauges using CMC and pluronic F127 formulations in comparison to basal media (p<0.001 in 242 
all formulations, and all needle gauges, Turkey’s multiple comparison tests and two-way 243 
ANOVA), with delivery increasing on average between 300-400% compared to particles 244 
delivered in basal media in the same needle gauge.  245 
We further explored needle blockage and injection failure for each of these formulations 246 
(Figure 2C) in needle gauges . Figure 2C demonstrates that the 0.25% pluronic F127 and 247 
0.25% CMC formulation had no injection failures compared to other formulations which 248 
occasionally resulted in a blocked needle injection failure. Considering this 0.25% pluronic 249 
F127 and 0.25% CMC formulation in more detail, we find that microparticle delivery is 250 
significantly increased in all needle gauges tested using this formulation compared to a basal 251 
media control (Figure 2D), with increases in delivery between 320-750% compared to basal 252 
media (Table 3), and an average increase in microparticle delivery of 520% across all needle 253 
gauges. This formulation is therefore broadly applicable to a range of clinical needle gauges.  254 
3.4 Modified viscosity formulations for the delivery of drug loaded microparticles  255 
We investigated the applicability of the lead 0.25% CMC 0.25% pluronic F127 formulation 256 
for the delivery of drug-eluting microparticles and microparticle-cell scaffold therapeutics. 257 
First, the release profile of amoxicillin from amoxicillin loaded  PLGA microparticles was 258 
tested, exploring microparticles delivered through a 27G needle with and without the 259 
modified viscosity formulation (Figure 3A). As expected, the total amount of amoxicillin 260 
released was increased when our delivery formulation was used. As the kinetics of release 261 
remained broadly unafected, we suggest that this is due to the increased delivery yield using 262 
the 0.25% CMC 0.25% pluronic F127 formulation.  263 
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Interestingly, the addition of pluronic acid and CMC may also alter microparticle surface 264 
wetting and shear forces experienced during ejection, which could also influence drug release 265 
kinetics.  The hydrophilicity of PLGA surfaces affects polymer degradation kinetics, and is 266 
correlated with both co-polymer composition and liquid solvent polarity.[36, 37] The addition of 267 
CMC and pluronic acid to the basal media formulation may alter the polarity of the liquid 268 
phase, and could directly impact microparticle surface wetting and so drug release kinetics. 269 
Formulations containing CMC and pluronic acid have also been shown to alter shear forces 270 
experienced by cells during stirred culture.[38, 39] The addition of these molecules to the 271 
formulation may therfore impact the shear forces particles are exposed to during ejection. To 272 
explore the relative importance of particle delivery yield, surface wetting, and ejection shear 273 
in controlling drug delivery, further studies should be performed to independently isolate 274 
these variables.  275 
3.5 Modified viscosity formulations for the delivery of microparticles-cell scaffolds  276 
Next, we investigated the effect of our modified viscosity formulation on cell viability. At low 277 
concentrations, both CMC and pluronic acid moietics have been shown to protect cells from 278 
detrimental effects due to exceesive shear forces.[38, 39] We examined the viability of human 279 
mesechmyal stem cells (MSCs) at 1 hour and 24 hours in media supplemented with our 280 
formulation. Figure 3B shows cell proliferation calibrated using the Presto Blue metabolic 281 
assay in both conditions. In both solutions, cells demonstrate a similar viability at 1 hour, and 282 
at 24 hours show a significant increase in metabolic activity compared to 1 hour. Cells 283 
remained viable in the formulation for up to 24 hours, though there was a reduction in 284 
metabolic activity after incubation for 24 hours in our formulation compared to basal media. 285 
At the 1 hour timepoint, which represents a realistic timeframe for the clinical administration 286 
of cell-particle systems, there was no significant difference in viability between cells cultured 287 
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in basal media and the 0.25% pluronic F127 0.25% CMC formulation, indicating this 288 
formulation may be suitable for the in vivo delivery of microparticle-cell systems. 289 
Finally, we investigated the delivery of cells together with PLGA microparticles through 290 
syringes, either with or without a 27G needle, in basal media or our 0.25% CMC and 0.25% 291 
pluronic F127 formulation. Figure 3C shows SEM images of cells delivered together with 292 
PLGA microparticle scaffolds, and demonstrates the integrity of both the particles and the 293 
cells post injection, and that the PLGA particles can be used to provide a scaffold for the cells. 294 
Figure 3D illustrates that in both needle free and  27G needle delivery systems, the use of the 295 
0.25% CMC and 0.25% pluronic F127 formulation significantly increased cell delivery by 296 
200-400% compared to basal media. These results are comparable to our earlier studies 297 
demonstrating enhanced delivery in microparticle only systems, and support our conclusion 298 
that basal media supplemented with 0.25% CMC and 0.25% pluronic F127 provides a 299 
formulation that can enhance delivery of PLGA microparticles, and microparticle-cell 300 
combination therapeutics, in needle delivery systems without compromising cell viability. We 301 
believe these results show the first needle delivery of a porous PLGA microparticle-MSC 302 
system, as proof-of-concept drug-eluting microparticle-cell scaffolds capable of combining a 303 
biodegradable cell support with localised drug delivery. Encapsulating soluble factors which 304 
direct host- or transplanted cell behaviour within these microparticle scaffolds would increase 305 
their versatility and make them a powerful tool for cell transplant. 306 
4. Conclusion  307 
The delivery of a controlled dose of microparticles is crucial for therapeutic applications. We 308 
find that the addition of viscosity modifiers can enhance particle delivery up to 520% across 309 
needle gauges between 21-30G, and identify a formulation of basal media supplemented with 310 
0.25% pluronic F127 and 0.25% CMC as providing an optimal system. Although the 311 
polymers explored here increase delivery across all needle sizes tested, our results indicate 312 
  
14 
 
that selection of an appropriate needle is also an important parameter to consider. We tested 313 
the biocompatibility of our lead formulation, finding that cells remain viable in the 314 
formulation for up to 24 hours, and demonstrate that this formulation is suitable for the 315 
improved in vitro delivery of drug eluting PLGA microparticles, and microparticle-cell 316 
scaffolds. These microparticle-cell scaffolds offer the potential to simultaneously support cells 317 
for transplant and modulate the host environment/transplanted cell behaviour through the 318 
controlled release of pharmaceuticals. Together, these results pave the way for further 319 
exploration of microparticle-cell scaffold and delivery systems for in vivo cell transplantation. 320 
Additionally, these results have important implications for the application of microparticle 321 
and microparticle-cell therapeutics, and may also apply to other polymer based 322 
pharmaceuticals or protein biologics delivered by needle. In many cases, in vitro testing and 323 
clinical applications use different delivery strategies, with different needle and formulation 324 
systems, which could lead to differences in administered therapeutic dose. In order to match 325 
in vitro, pre-clinical and therapeutic outcomes, administration parameters (such as needle 326 
diameter and delivery formulation) should be carefully considered, and ideally conserved 327 
between pre-clinical and therapeutic applications.   328 
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Figure 1: Properties of pluronic F127 and CMC modified solutions (A) Size distribution 443 
of PLGA microparticles used in this study, measured by laser diffraction. (B) PLGA 444 
microparticle delivery from a stock of 5mg/ml through syringes fitted with various needle 445 
gauges  (C, D, E) Increasing concentrations of pluronic F127 (C) CMC (D) and pluronic 446 
F127/CMC combination formulations (E) were tested for their ability to deliver microparticles 447 
from a stock solution through 27G needles (F) Viscosity measurements at increasing shear 448 
rate, measured for combination formulations at 25⁰C. All statistical tests show one way 449 
ANOVA where  p>0.05 *, p>0.01 **, p>0.001 ***, p>0.0001 ****, bars represent mean of 3-450 
6 repeats with SEM error bars.  451 
 452 
 453 
  454 
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Figure 2: Modified solutions across needle gauges. Increasing concentrations of (A) 455 
pluronic F127/CMC combination formulations were tested for their ability to deliver 456 
microparticles from a stock solution across a range of needle gauges. (B) Average delivery of 457 
microparticles across all needle gauges (21-27G) in different combination formulations. (C) 458 
Number of needle blockages in each formulation, n=10 for each formulation. Needles 30G, 459 
27G, 25G, 23G and 21G were tested, with blockages found in 25-30G.  (D) A comparison 460 
between basal media and 0.25% pluronic 0.25% CMC for the delivery of microparticles 461 
across needle gauges 21G-27G. All statistical tests show two way ANOVA where  p>0.05 *, 462 
p>0.01 **, p>0.001 ***, p>0.0001 ****, bars represent mean of 3-6 repeats with SEM error 463 
bars. 464 
465 
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Figure 3: Effect of modified formulations on drug release and cell behaviour  (A) 466 
Cumulative amoxicillin release was analysed from PLGA microparticles delivery using 467 
syringes fitted 27G needles. PLGA microparticles were suspended in basal media or 0.25% 468 
pluronic 0.25% CMC supplemented media (B) SEM image of microparticle cell scaffold post-469 
delivery through a 27G needle. Scale bar 10µm. (C,D) Cell number after cellular incubation 470 
in basal media, or media supplemented with 0.25% CMC and 0.25% pluronic F127 after 1 471 
and 24 hours compared to an initial seeding density (C), (D) Cell number post simulated 472 
delivery through a needle free of 27G needle system using basal media or media 473 
supplemented with 0.25% CMC and 0.25% pluronic F127. Statistical analysis performed 474 
using ANOVA, all statistical tests show p>0.05 *, p>0.01 **, p>0.001 ***, p>0.0001 ****, 475 
bars represent mean of 3-6 repeats with SEM error bars. 476 
 477 
  478 
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Table 1: Clinical needle guages and needle bore internal diameters  479 
Needle 
Guage 
Needle bore 
diameter 
(mm) 
Needle 
Guage 
Needle bore 
diameter 
(mm) 
15 1.372 25 0.260 
16 1.194 26 0.260 
17 1.067 27 0.210 
18 0.838 28 0.184 
19 0.686 29 0.184 
20 0.603 30 0.159 
21 0.514 31 0.133 
22 0.413 32 0.108 
23 0.337 33 0.108 
24 0.311 34 0.0826 
Table 2: Calculated shear rate through clinical needle gauges at varying flow Shear rate 480 
was calculated using Poiseuilles equation for needle gauges between  21-30G, using 481 
experimental flow rates tested using 1 mm/s plunger speed, and theoretical flow rates of 1 or 482 
20 ml/hour, all values rounded to 3 significant figures. 483 
Needle 
gauge 
Needle 
diameter 
(cm) 
Experimental flow 
 (plunger at 1mm/s) 
Theoretical flow 
 (1 ml/hour) 
Theoretical flow 
(20 ml/hour)  
Q (cm3/s) Shear rate (s-1) Shear rate (s-1) Shear rate (s-1) 
30G 0.159 1.98E-07 503 704000 14100000 
27G 0.210 3.46E-07 380 306000 6110000 
25G 0.260 5.31E-07 308 161000 3220000 
23G 0.337 8.92E-07 237 74000 1480000 
21G 0.514 2.07E-06 156 20800 417000 
Table 3: Delivery efficacy Delivery efficacy was calculated by comparing the number of 484 
particles delivered. For example, PLGA microparticles were suspended in either basal media, 485 
or media supplemented with 0.25% CMC and 0.25% Pluronic F127, loaded into a standard 486 
syringe fitted with the appropriate gauge needle. Syringes were loaded onto the mechanically 487 
controlled syringe pump, and ejected. An aliquot of the ejected solution was transferred to a 488 
hemocytometer and the number of ejected particles counted. At least three syringe ejections 489 
were tested for each condition, and delivery efficacy calculated by comparing to the number 490 
of particles ejected in the basal media formulation.  491 
 492 
Needle system and 
media 
composition 
Average 
number of 
particles 
delivered/ mL  
Compare to: Needle system 
and media composition 
Average 
number of 
particles 
delivered/ mL  
Calculated 
delivery 
efficacy (%) 
Needle free, basal 
media 0.90 x106 
Needle free, 0.25% CMC 
0.25% pluronic F127 4.95 x106 550% 
21G, basal media 0.94 x106 
21G, 0.25% CMC 0.25% 
pluronic F127 5.06 x106 538% 
23G, basal media 1.17 x106 
23G, 0.25% CMC 0.25% 
pluronic F127 4.96 x106 424% 
25G, basal media 1.29 x106 
25G, 0.25% CMC 0.25% 
pluronic F127 4.08 x106 316% 
27G, basal media 0.55 x106 
27G, 0.25% CMC 0.25% 
pluronic F127 2.91 x106 529% 
30G, basal media 0.58 x106 
30G, 0.25% CMC 0.25% 
pluronic F127 4.37 x106 753% 
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